Sanofi India has posted a sharp jump in quarterly earnings, with its diabetes franchise and a fast-growing public sector business doing most of the heavy lifting. The Mumbai-listed subsidiary of the French drugmaker, which follows a calendar financial year, reported results for the July–September 2026 quarter (Q3 2026) on 29 October and declared an interim dividend of ₹75 per share.

The numbers

• Profit for the period: ₹117 crore, up 53.6% from ₹76 crore in Q3 2025, and up about 40% sequentially from ₹83.5 crore in Q2 2026.
• Revenue from operations: ₹491.7 crore, up 3.4% year on year from ₹475.4 crore and up 12.3% over the previous quarter.
• EBITDA: ₹161 crore, up 20.1%, with the margin widening to 32.8% from 28.2% a year earlier.
• Net sales: total net sales grew 4%, with domestic net sales up 2%.

The gap between modest top-line growth and a much faster rise in profit points to better margins rather than a surge in volumes. Total expenses rose only 2.4% quarter on quarter, to ₹339.5 crore, even as revenue climbed more than 12%.

Insulin keeps the engine running

Diabetes remains the core of Sanofi India’s business. The insulin portfolio, which includes Lantus, Toujeo, Apidra and Soliqua, grew 9% in the quarter, and the company said its diabetes injectables hold a 55% share of their market in India.

“Our diabetes business is firmly in momentum, growing in double digits quarter-on-quarter (at a YTD-level),” said Managing Director Deepak Arora.

Public sector sales up 85%

The standout line was the public sector business, which grew 85% on the back of new institutional accounts in the innovative insulin analogue segment. For a market where government procurement is a growing channel for chronic-disease medicines, the shift matters: it widens access to newer analogues beyond private retail pharmacies.

“Our acceleration in the public sector shows that we are not just growing, we are widening access to innovative therapies across the country,” Arora said.

Exports also posted double-digit growth, while revenue from Sanofi India’s strategic partnerships in cardiovascular, oral anti-diabetes and central nervous system therapies was broadly stable.

Dividend and market reaction

The board declared an interim dividend of ₹75 per equity share of face value ₹10 for financial year 2026, with 5 November 2026 fixed as the record date. Investors welcomed the results: the stock closed 7.02% higher at ₹3,202 on 29 October, though it remains about 22% lower for the year to date.

Why it matters for Indian pharma

Sanofi India’s quarter is a reminder of how large and contested India’s diabetes market has become, and how much institutional demand now shapes it. With the country’s diabetic population continuing to grow, multinational and domestic players alike are competing on access, pricing and supply into government programmes, as well as on newer analogue and combination therapies. Steady margin gains on flat-to-modest sales growth also show the operating discipline that listed pharma subsidiaries are leaning on as the domestic market matures.

Sources: Sanofi India exchange filing and press release; CNBC-TV18, 29 October 2026.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!